MX2010006694A - Formulacion de liberacion controlada, preventiva de mal uso. - Google Patents

Formulacion de liberacion controlada, preventiva de mal uso.

Info

Publication number
MX2010006694A
MX2010006694A MX2010006694A MX2010006694A MX2010006694A MX 2010006694 A MX2010006694 A MX 2010006694A MX 2010006694 A MX2010006694 A MX 2010006694A MX 2010006694 A MX2010006694 A MX 2010006694A MX 2010006694 A MX2010006694 A MX 2010006694A
Authority
MX
Mexico
Prior art keywords
controlled release
core
release formulation
active agent
pharmaceutically active
Prior art date
Application number
MX2010006694A
Other languages
English (en)
Inventor
Sonia Gervais
Miloud Rahmouni
Damon Smith
Vinayak Sant
Fouzia Soulhi
Ali Bichara
Freferic Duffayet
Shams Rustoms
Ali El-Jammal
Bobby-Ernst Boursiquot
Jean-Michel Ndong
Angela Ferreda
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Publication of MX2010006694A publication Critical patent/MX2010006694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe una formulación de liberación controlada preventiva de mal uso que comprende un núcleo que comprende un material superabsorbente (por ejemplo, policarbofilo), un recubrimiento de liberación controlada que rodea el núcleo, y una pluralidad de microparticulas de liberación controlada que tienen un agente farmacéuticamente activo (por ejemplo, un analgésico opioide) dispuesto dentro de el núcleo, el recubrimiento o el núcleo y el recubrimiento. Cuando se aplasta, en forma intencional o accidental, y se expone a un medio acuoso, el material superabsorbente presente en el núcleo aumenta de tamaño para encapsular las micropartículas, que se mantienen sustancialmente intactas por lo que retardan la liberación del agente farmacéuticamente activo de la formulación. También se describe un método para usar la formulación de liberación controlada preventiva de mal uso para suministrar un agente farmacéuticamente activo a un mamífero, por ejemplo, un humano, que lo necesite.
MX2010006694A 2007-12-17 2008-12-16 Formulacion de liberacion controlada, preventiva de mal uso. MX2010006694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1429607P 2007-12-17 2007-12-17
PCT/CA2008/002200 WO2009076764A1 (en) 2007-12-17 2008-12-16 Misuse preventative, controlled release formulation

Publications (1)

Publication Number Publication Date
MX2010006694A true MX2010006694A (es) 2010-09-07

Family

ID=40795147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006694A MX2010006694A (es) 2007-12-17 2008-12-16 Formulacion de liberacion controlada, preventiva de mal uso.

Country Status (13)

Country Link
US (7) US8486448B2 (es)
EP (1) EP2219612A4 (es)
JP (1) JP5651818B2 (es)
KR (1) KR20100121463A (es)
CN (1) CN101969930A (es)
AR (1) AR069905A1 (es)
AU (1) AU2008338207A1 (es)
BR (1) BRPI0821732A2 (es)
CA (1) CA2707980C (es)
MX (1) MX2010006694A (es)
RU (1) RU2010129907A (es)
TW (1) TW200934532A (es)
WO (1) WO2009076764A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
KR20100121463A (ko) * 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2010028489A1 (en) * 2008-09-15 2010-03-18 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
KR20110119845A (ko) * 2008-10-27 2011-11-02 알자 코퍼레이션 지속 방출형 경구용 아세트아미노펜/트라마돌 제형
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102770127B (zh) * 2010-02-24 2015-04-15 思玛化验室公司 抗滥用制剂
SG183993A1 (en) * 2010-03-09 2012-10-30 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions
AR082167A1 (es) * 2010-07-14 2012-11-14 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2736497B1 (en) * 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
PL2838516T3 (pl) 2012-04-18 2019-05-31 SpecGx LLC Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
CN104768552A (zh) * 2012-09-03 2015-07-08 第一三共株式会社 含有盐酸氢吗啡酮的口服持续释放药物组合物
CA2791206A1 (en) * 2012-09-28 2014-03-28 Pharmascience Inc. Abuse deterrent pharmaceutical formulation
CN107595793B (zh) 2012-11-30 2020-11-13 阿库拉制药公司 活性药物成分的自调节释放
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US20160193182A1 (en) * 2013-08-14 2016-07-07 Evonik Roehm Gmbh Coating composition
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP6850131B2 (ja) 2014-07-03 2021-03-31 スペックジーエックス エルエルシー 非セルロース多糖を含む、乱用抑止性即時放出製剤
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
GB2567493B (en) * 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
KR20200078601A (ko) * 2017-11-01 2020-07-01 엣지몬트 파마슈티칼스 엘엘씨 트러스트 로라제팜의 내알코올성 경구 약제학적 조성물
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ANTI-ABUSE IMMEDIATE RELEASE CAPSULES DOSAGE FORMS
WO2020086673A1 (en) * 2018-10-26 2020-04-30 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
EP3907253A4 (en) * 2019-12-20 2022-04-06 LG Chem, Ltd. SUPER-ABSORBENT RESIN COMPOSITION
US20220193634A1 (en) * 2019-12-20 2022-06-23 Lg Chem, Ltd. Preparation method of super absorbent polymer composition
JP7321627B2 (ja) * 2019-12-20 2023-08-07 エルジー・ケム・リミテッド 高吸水性樹脂組成物の製造方法
WO2021150095A1 (ko) * 2020-01-20 2021-07-29 주식회사 엘지화학 고흡수성 수지의 제조 방법
CN115702888A (zh) * 2021-08-13 2023-02-17 合肥立方制药股份有限公司 一种盐酸羟考酮渗透泵缓释片及其制备方法
CN115707455A (zh) * 2021-08-18 2023-02-21 越洋医药开发(广州)有限公司 允许睡眠调节类药物分段释放的片剂及其制备方法
CA3230828A1 (en) * 2021-09-16 2023-03-23 David S. Soane Swellable polymeric materials and useful articles incorporating same

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004613A (en) 1956-05-17 1961-10-17 Milburn R Simmons Electronic deep hole condition analyser
US3773995A (en) 1972-10-27 1973-11-20 Westinghouse Electric Corp Motor advanced spring charging pawl and ratchet mechanism with spring assist
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2772695B2 (ja) * 1990-01-26 1998-07-02 日水製薬株式会社 ３層錠
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
DK0566709T5 (da) * 1991-09-06 2009-05-18 Ortho Mcneil Janssen Pharm Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6159501A (en) 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
DK1041987T3 (da) * 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
HUP0100310A3 (en) * 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
AU776645B2 (en) 1999-03-31 2004-09-16 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
RS50407B (sr) * 2000-02-08 2009-12-31 Euro-Celtique S.A., Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2001085285A1 (en) 2000-05-10 2001-11-15 Armstrong Brad A Analog controls for wrist watches
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
AU2002227383B2 (en) * 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
DE60216078T2 (de) 2001-05-11 2007-07-05 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US6968551B2 (en) 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
DE20220910U1 (de) 2001-08-06 2004-08-05 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
MXPA04001210A (es) * 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20030049317A1 (en) * 2001-08-30 2003-03-13 Lindsay David R. Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030125347A1 (en) * 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US20060034872A1 (en) * 2002-04-29 2006-02-16 Woolf Clifford J Compositions and methods for preventing abuse of orally administered medications
CA2486075A1 (en) 2002-05-13 2003-11-20 Endo Pharmaceuticals Inc. Abuse-resistant opioid solid dosage form
WO2004041154A2 (en) 2002-05-13 2004-05-21 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
KR100522239B1 (ko) 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
WO2004026308A1 (fr) * 2002-09-21 2004-04-01 Shuyi Zhang Compose d'acetamidophenol et de tramadol a liberation prolongee
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
ES2371462T3 (es) 2003-01-13 2012-01-03 Shire Llc Conjugados de carbohidratos para prevenir el abuso de sustancias controladas.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CN100588391C (zh) * 2003-08-12 2010-02-10 恩德制药公司 抗药物滥用的单个长效缓释片剂
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
NZ546182A (en) * 2003-09-26 2009-08-28 Alza Corp Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen
AU2004314693B2 (en) * 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP2264863B1 (de) 2003-11-13 2020-01-08 SEW-EURODRIVE GmbH & Co. KG Kompaktantrieb, spiroplangetriebe und verfahren zur fertigung eines antriebs
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
SI1691892T1 (sl) 2003-12-09 2007-08-31 Euro Celtique Sa Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
KR100963914B1 (ko) * 2004-03-30 2010-06-17 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
EP1584335A3 (en) 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
FR2878158B1 (fr) 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US7191215B2 (en) 2005-03-09 2007-03-13 Marquee, Inc. Method and system for providing instantaneous media-on-demand services by transmitting contents in pieces from client machines
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
WO2007013975A2 (en) 2005-07-20 2007-02-01 Pharmorx Inc. Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
PL2402005T3 (pl) * 2005-08-24 2021-11-22 Endo Pharmaceuticals Inc. Formulacje nalbufiny o przedłużonym uwalnianiu
US8795723B2 (en) * 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
CN101370485A (zh) * 2006-01-21 2009-02-18 艾博特股份有限两合公司 用于滥用药物给药的剂型和方法
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
EP1993519A4 (en) 2006-03-15 2011-12-21 Acura Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR PREVENTING THE ABUSE OF ORGANIC PRODUCTS MANIPULATED ORAL
JP4953673B2 (ja) * 2006-03-22 2012-06-13 リンテック株式会社 経口投与剤
US20070237816A1 (en) 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR20100121463A (ko) 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
AU2009327312A1 (en) * 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation

Also Published As

Publication number Publication date
EP2219612A1 (en) 2010-08-25
US20090175937A1 (en) 2009-07-09
US8486448B2 (en) 2013-07-16
EP2219612A4 (en) 2013-10-30
RU2010129907A (ru) 2012-01-27
CN101969930A (zh) 2011-02-09
CA2707980C (en) 2015-05-12
AR069905A1 (es) 2010-03-03
JP2011506493A (ja) 2011-03-03
US20150272890A1 (en) 2015-10-01
US20140193494A1 (en) 2014-07-10
US8920833B2 (en) 2014-12-30
AU2008338207A1 (en) 2009-06-25
JP5651818B2 (ja) 2015-01-14
KR20100121463A (ko) 2010-11-17
US20180185292A1 (en) 2018-07-05
US8691270B2 (en) 2014-04-08
CA2707980A1 (en) 2009-06-25
WO2009076764A1 (en) 2009-06-25
US8920834B2 (en) 2014-12-30
TW200934532A (en) 2009-08-16
US20130344142A1 (en) 2013-12-26
US20140294954A1 (en) 2014-10-02
BRPI0821732A2 (pt) 2015-06-16
US20160367483A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
MX2010006694A (es) Formulacion de liberacion controlada, preventiva de mal uso.
WO2009000216A3 (es) Un dispositivo de ruptura de liberación controlada que comprende una subcapa
IL187475A (en) A form of oral administration containing one population of micro-particles to release a variable of at least one active anesthetic and a second population of micro-particles containing at least one depressant and their use
DE60238756D1 (de) Opioid enthaltende arzneiform gegen missbrauch
NZ610701A (en) Once daily formulation of lacosamide
WO2012085656A3 (en) Encased tamper resistant controlled release dosage forms
HK1141441A1 (en) Sustained release pellets comprising wax-like material
NZ609840A (en) Process for making multiparticulate gastroretentive dosage forms
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
MX2013000707A (es) Metodo y aparato de supresion de incendios de etapa dual no electrica.
WO2009059701A3 (de) Retardtabletten mit hydromorphon
WO2008118133A3 (en) Silk microspheres for encapsulation and controlled release
WO2011101866A3 (en) Gastric retention formulation containing baclofen
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
RU2013117274A (ru) Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
NZ602000A (en) Methods and compositions to treat hemorrhagic conditions of the brain
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2007083323A3 (en) Modified release oral dosage form comprising desmopressin
WO2009149058A3 (en) Modified release niacin formulations
WO2007057508A3 (en) Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
WO2013035081A3 (de) Formulierung zur kontrollierten freisetzung eines oder mehreren stoffe im verdauungstrakt eines säugetiers
TN2012000623A1 (en) Particle coating preparation
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
WO2011090725A3 (en) Gastroretentive solid oral dosage forms with swellable hydrophilic polymer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal